Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 July 2007Website:
http://www.arbutusbio.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 0 min agoDividend
Analysts recommendations
Institutional Ownership
ABUS Latest News
WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its third quarter 2024 financial results and corporate update for Wednesday, November 6, 2024. The schedule for the press release and conference call/webcast are as follows:
WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:
Here is how Arbutus Biopharma (ABUS) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
Biotechnology firm Arbutus (NASDAQ: ABUS ) — which specializes in virology — announced a major overhaul of its business. It will dramatically cut headcount in an effort to streamline operations and focus on its most promising therapeutic candidates.
Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q2 2024 Earnings Conference Call August 1, 2024 8:45 AM ET Company Participants Lisa Caperelli - VP, Investor Relations Michael McElhaugh - Interim President, CEO & Director Karen Sims - Chief Medical Officer David Hastings - CFO Conference Call Participants Dennis Ding - Jefferies Roy Buchanan - JMP Securities Keay Nakae - Chardan Capital Markets Operator Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2024 Second Quarter Financial Results and Corporate Update.
End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its second quarter 2024 financial results and corporate update for Thursday, August 1, 2024. The schedule for the press release and conference call/webcast are as follows:
Arbutus Biopharma's three-pronged strategy targets cHBV by suppressing HBV DNA, reducing viral antigens, and boosting immune response. Imdusiran (AB-729) shows promise in Phase 2 trials, potentially leading to a functional cure for chronic hepatitis B. ABUS is engaged in significant IP litigation with Moderna, Pfizer, and BioNTech over LNP technology used in mRNA vaccines.
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment
- 1(current)
- 2
What type of business is Arbutus Biopharma?
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
What sector is Arbutus Biopharma in?
Arbutus Biopharma is in the Healthcare sector
What industry is Arbutus Biopharma in?
Arbutus Biopharma is in the Biotechnology industry
What country is Arbutus Biopharma from?
Arbutus Biopharma is headquartered in United States
When did Arbutus Biopharma go public?
Arbutus Biopharma initial public offering (IPO) was on 26 July 2007
What is Arbutus Biopharma website?
https://www.arbutusbio.com
Is Arbutus Biopharma in the S&P 500?
No, Arbutus Biopharma is not included in the S&P 500 index
Is Arbutus Biopharma in the NASDAQ 100?
No, Arbutus Biopharma is not included in the NASDAQ 100 index
Is Arbutus Biopharma in the Dow Jones?
No, Arbutus Biopharma is not included in the Dow Jones index
When was Arbutus Biopharma the previous earnings report?
No data
When does Arbutus Biopharma earnings report?
The next expected earnings date for Arbutus Biopharma is 07 November 2024